TC BioPharm, a biotechnology company in the clinical stage, has recently announced its intention to acquire a privately-held biotechnology company. This company specializes in the development of Chimeric Antigen Receptor T-cell (CAR-T) therapies for refractory cancers and solid tumors. This agreement marks the second such acquisition for TCBP in recent months, signaling its commitment to expanding its therapeutic offerings.

CAR T-cell therapy involves modifying a patient's immune cells to enhance their ability to detect and destroy cancer cells. The target company has developed proprietary methods to improve CARs' targeting of solid tumors. Preclinical data for its lead CAR-T candidate shows promise across various solid tumors, including colorectal, pancreatic, mesothelioma, ovarian, and breast cancer. Additionally, the target company is developing an allogeneic CAR-T therapy for autoimmune diseases.

However, the completion of this acquisition is contingent upon various factors, including securing adequate financing and obtaining necessary approvals.

TC BioPharm, expressed satisfaction with the potential acquisition, highlighting synergies between the companies and the benefits it would bring to the combined entity's therapeutic platform. He emphasized the potential for advancing solid tumor assets and expanding into autoimmune disease treatments, leveraging expertise in gamma-delta T-cells, CAR engineering, and clinical development.

This acquisition is seen as a strategic move to strengthen the company's pipeline and intellectual property portfolio, with potential significant milestones expected in 2024 and 2025 across various indications. Kobel expressed confidence in the company's ability to navigate the challenging capital market environment and capitalize on complementary resources to enhance overall value.

 

Source: prnewswire.com

Report Abuse